Small Caps - Canada’s Post

The development of an AI model to enhance tumor removal accuracy during breast cancer surgery is a significant advancement in the field of oncology. The AI model can assist surgeons in accurately identifying and removing tumors, potentially reducing the risk of leaving cancerous tissue behind. By providing real-time guidance during surgery, the AI model may contribute to improved decision-making and surgical outcomes. Tailoring the surgery to individual patient needs based on AI analysis may lead to more personalized and effective treatments. The use of AI can potentially streamline the surgical process, saving time and resources. It's important to note that the success and adoption of such AI models would depend on rigorous testing, validation, and integration into standard medical practices.

The diagnosis and treatment of cancer remains a critical priority for healthcare professionals around the world.   By putting digital pathology directly into the hands of surgeons as the operate, we can help facilitate on-the-spot decision making, treatment adjustments and precision surgery.   “We are particularly excited by what the InVue™, which tailors our patented technology to the surgical market, will mean for the future treatment and diagnosis of cancer patients. It will facilitate a dramatic step forward in the way cancer can be diagnosed and treated with unprecedented accuracy and precision. Our first intended use of InVue™ is for breast cancer surgery and margin determination. This form of cancer is the most commonly diagnosed cancer amongst women in Australia, with over 20,000 Australians diagnosed with breast cancer each year. In the US, this number is as high as 300,000.” said Dr Camile Farah, CEO and Managing Director of Optiscan Imaging Ltd.   Find out more: https://lnkd.in/geRCYeN9 #optiscan #OIL #optiscanimaging #digitalpathology #InVue

Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) announced impressive results from a peer-reviewed retrospective study which examined the integration of wide field optical coherence tomography (WF-OCT) with the company’s proprietary investigation ImgAssist #AI technology. The company said that the study showed its AI algorithm when integrated in the WF-OCT accurately identified 96.8% of pathology-positive breast cancer margins. Perimeter said these results demonstrated the clinical viability of AI-enhanced margin visualization using WF-OCT in breast cancer surgery and its potential to decrease reoperation rates due to residual tumors. “We have a training dataset of several million proprietary images of both cancerous and healthy tissue captured with our OCT imaging technology,” Perimeter CEO Adrian Mendes said in a statement. More at #Proactive #ProactiveInvestors #TSXV #OTC #PINK #PYNKF http://ow.ly/pjVB105k92O

Read about how Perimeter Medical Imaging AI is using AI to help surgeons remove all breast cancerous cells on the first surgery. #AI #healthcareinnovations

Exploring the Frontiers of Breast Cancer Surgery: Perimeter Medical Imaging AI's groundbreaking S-Series and B-Series OCT devices are not just technological advancements; they are beacons of hope in the fight against breast cancer. Our latest article delves into how these innovations are poised to lower reoperation rates and improve patient outcomes in Canada. Plus, get an insight into Perimeter's financial trajectory and its potential in transforming breast cancer treatment. A must-read for healthcare professionals, investors, and technology enthusiasts. #HealthcareInnovation #BreastCancerAwareness #MedicalTechnology Perimeter Medical Imaging AI https://bit.ly/3tiJeUC

Our peer-reviewed publication on the novel use of wide-field OCT and AI as a one-two combo punch to tackle breast cancer surgical oncology margins is out! You can read the details in the paper but the key statistics is 97% pathology positive margin identification while achieving 93% sensitivity and 98% specificity. Compare this number to the published results revealing 21.1% and 14.9% reoperation rates among commercially insured patients and the Medicare cohort (bit.ly/3wwMkp1). Many thanks to my co-authors Yanir Levy, David Rempel, Mark Nguyen, Ali Yassine, Maggie Sanati-Burns, Dr Payal Salgia, Bryant Lim, Sarah Butler, PhD, and Andrew Berkeley. Perimeter Medical Imaging AI, #AI, #OCT #breastcancer #margin #oncology #surgical

We are excited to announce that Optiscan Imaging Ltd has received ethical clearance from the Royal Melbourne Hospital Human Research Ethics Committee to commence an in vivo clinical study focused on breast cancer. This study will showcase the capabilities of our recently unveiled InVue™ precision surgery imaging platform. The InVue™ device will be used during surgeries to collect real-time imaging data of the surgical cavity after tumor removal, aiming to determine the clearance of the tumor on the spot. Optiscan CEO and Managing Director, Dr. Camile Farah, stated: “This non-interventional study design allows us to gather valuable imaging data without interfering with standard care. We anticipate progressing to an interventional protocol, where collected images will guide surgeons in real-time decision-making for optimal patient outcomes.” Stay tuned for more updates as we continue to advance precision surgery and improve patient care. https://lnkd.in/gQz2e2HW #Optiscan #BreastCancer #InVue #PrecisionSurgery #MedicalInnovation #Healthcare

New published paper! This peer-reviewed study highlights the potential for #AI and wide-field (WF) OCT in breast cancer surgery to enhance productivity and decision making in surgical margin assessment, decreasing reoperation rates due to residual cancer. The results suggest the investigational* deep learning model accurately identified 96.8% of pathology positive margins in WF-OCT images with high sensitivity and specificity. Read it at https://lnkd.in/dmxWFTCM. #artificialintelligence #AI #deeplearning #healthcareinnovation #breastcancer -- *CAUTION. Investigational Device. Subject to U.S. Law. Not available for sale in the United States.

📃Scientific paper: Development and evaluation of a Japanese prediction model for low anterior resection syndrome after rectal cancer surgery Abstract: BACKGROUND: Low anterior resection syndrome (LARS) is the most common complication after rectal cancer resection. We aimed to identify LARS' predictive factors and construct and evaluate a predictive model for LARS. METHODS: This retrospective study included patients with rectal cancer more than 1 year after laparoscopic or robotic-assisted surgery. We administered a questionnaire to evaluate the degree of LARS. In addition, we examined clinical characteristics with univariate and multivariate analysis to identify predictive factors for major LARS. Finally, we divided the obtained data into a learning set and a validation set. We constructed a predictive model for major LARS using the learning set and assessed the predictive accuracy of the validation set. RESULTS: We reviewed 160 patients with rectal cancer and divided them into a learning set (n = 115) and a validation set (n = 45). Univariate and multivariate analyses in the learning set showed that male (odds ratio [OR]: 2.88, 95% confidence interval [95%CI] 1.11–8.09, p = 0.03), age < 75 years (OR: 5.87, 95%CI 1.14–47.25, p = 0.03) and tumors located < 8.5 cm from the AV (OR: 7.20, 95%CI 2.86–19.49, p < 0.01) were significantly related to major LARS. A prediction model based on the patients in the learning set was well-calibrated. CONCLUSIONS: We found that sex, age, and tumor location were independent predictors of major LARS in Japanese patients that underwent rectal cancer surgery. Our predictive model fo... Continued on ES/IODE ➡️ https://etcse.fr/uV72 ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Who is the best robotic cancer surgeon in India: Navigating Cancer Surgery? #drsurenderdabas.com Introducing Dr. Surender Dabas — Pioneering Excellence in Robotic Cancer Surgery Embark on a transformative journey towards healing and hope with Dr. Surender Dabas, your beacon of excellence in robotic cancer surgery. Renowned as the best robotic cancer surgeon in India, Dr. Dabas combines cutting-edge technology with unparalleled expertise to redefine the landscape of medical innovation. With a profound commitment to patient well-being. Dr. Surender Dabas is dedicated to delivering personalized, compassionate care, ensuring each individual’s unique journey through cancer treatment is met with the highest standards of precision and proficiency. Why Choose Dr. Surender Dabas as best robotic cancer surgeon in India? ✨ Innovative Technology: Dr. Dabas employs state-of-the-art robotic surgical systems, ensuring minimally invasive procedures and faster recovery times. ✨ Expertise and Experience: With a wealth of experience in oncology and a specialized focus on robotic surgery, Dr. Dabas is a trailblazer in the field, having successfully treated numerous patients. ✨ Patient-Centric Approach: Driven by empathy, Dr. Surender Dabas prioritizes patient comfort and well-being throughout the entire treatment process. ✨ Comprehensive Cancer Care: From diagnosis to post-operative care, Dr. Dabas provides holistic cancer care, ensuring a seamless and supportive journey for each patient. Frequently Asked Questions About best robotic cancer surgeon in India: Q1: What makes robotic surgery different from traditional surgery? Robotic surgery, including the utilization of the best robotic cancer surgeon in India, involves the use of advanced robotic systems. This innovative approach enables enhanced precision, smaller incisions, and quicker recovery times compared to traditional methods. Q2: Is robotic surgery suitable for all types of cancer? While not suitable for every case, robotic surgery is applicable to many cancer types, offering a minimally invasive alternative in appropriate situations. Dr. Dabas evaluates each case individually to determine the most suitable approach. Q3: How long does the recovery process take after robotic cancer surgery? Recovery times vary based on the procedure and individual patient factors. However, patients generally experience shorter hospital stays and faster recovery compared to traditional surgery. . . . #bestroboticcancersurgeoninmeerut #bestroboticcancersurgeoninkarnal #bestroboticcancersurgeoninindia